Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (381-390 of 436) with videos related to

Pageof 44
Sort By:
Frontiers in Oncology|February 15, 2021
Next-Generation Sequencing of <i>DDX41</i> in Myeloid Neoplasms Leads to Increased Detection of Germline AlterationsSarah A Bannon, Mark J Routbort, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative AnalysisNaval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Leukemia|July 14, 2023
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapiesBranko Cuglievan, Jeremy Connors, Jiasen He, et al.
Pageof 44

Showing results (381-390 of 436) with videos related to

Sort By:
Pageof 44
Frontiers in Oncology|February 15, 2021
Next-Generation Sequencing of <i>DDX41</i> in Myeloid Neoplasms Leads to Increased Detection of Germline AlterationsSarah A Bannon, Mark J Routbort, Guillermo Montalban-Bravo, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative AnalysisNaval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Cancer|April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Leukemia|March 12, 2026
Immunophenotypic changes following menin inhibition in acute myeloid leukemiaSanam Loghavi, Aziz Farhat, Trevor J Jamison, et al.
Leukemia|July 14, 2023
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapiesBranko Cuglievan, Jeremy Connors, Jiasen He, et al.
Pageof 44